Evidence map›Paper›PMID 38289720›Full record

ArticleEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2024

Economic analyses in cardiac electrophysiology: from clinical efficacy to cost utility.

Maria Hee Jung Park Frausing, Jens Cosedis Nielsen, Caroline Louise Westergaard, Christian Gerdes, Jakob Kjellberg, Giuseppe Boriani, Mads Brix Kronborg

Open access · hybridAbstract read
In one paragraph

Article in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 7 citations in OpenAlex.

  1. Cost-effectiveness of apixaban vs. aspirin for the reduction of thrombo-embolism in high-risk patients with device-detected atrial fibrillation: insights from the ARTESiA trial.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025
    Trial
  2. Improved patient value after implementing same day discharge for patients undergoing pulmonary vein isolation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Article
  3. Review
  4. Review
  5. Same-day discharge after electrophysiological and cardiac implantable electronic device procedures: a clinical consensus statement of the European Heart Rhythm Association (EHRA) and the Association of Cardiovascular Nursing & Allied Professions (ACNAP) of the ESC.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Review
  6. Public procurement of cardiac implantable electronic devices across Europe: are we purchasing value or cost-effectiveness?Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Article
  7. Cost-effectiveness of atrial fibrillation screening programmes across European nations.European heart journal. Quality of care & clinical outcomes · 2026
    Article
  8. Cost-effectiveness of atrial fibrillation screening programmes across European nations.European heart journal. Quality of care & clinical outcomes · 2026
    Article
  9. Review
  10. Review
  11. Apixaban in subclinical atrial fibrillation: stroke-driven value amid economic uncertainty.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Maria Hee Jung Park FrausingDepartment of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Bvld 99, DK-8200 Aarhus, Denmark.ORCID 0000-0003-2026-1032
Jens Cosedis NielsenDepartment of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Bvld 99, DK-8200 Aarhus, Denmark.ORCID 0000-0003-0631-0010
Caroline Louise WestergaardCardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy.
Christian GerdesDepartment of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Bvld 99, DK-8200 Aarhus, Denmark.ORCID 0000-0001-7658-109X
Jakob KjellbergThe Danish Center for Social Science Research, VIVE, Copenhagen, Denmark.ORCID 0000-0003-4336-2397
Giuseppe BorianiCardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy.ORCID 0000-0002-9820-4815
Mads Brix KronborgDepartment of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Bvld 99, DK-8200 Aarhus, Denmark.ORCID 0000-0003-1672-222X
Aarhus University · DKUniversity of Modena and Reggio Emilia · ITAarhus University Hospital · DKVIVE - The Danish Center for Social Science Research · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiac electrophysiology is an evolving field that relies heavily on costly device- and catheter-based technologies. An increasing number of patients with heart rhythm disorders are becoming eligible for cardiac interventions, not least due to the rising prevalence of atrial fibrillation and increased longevity in the population. Meanwhile, the expansive costs of healthcare face finite societal resources, and a cost-conscious approach to new technologies is critical. Cost-effectiveness analyses support rational decision-making in healthcare by evaluating the ratio of healthcare costs to health benefits for competing therapies. They may, however, be subject to significant uncertainty and bias. This paper aims to introduce the basic concepts, framework, and limitations of cost-effectiveness analyses to clinicians including recent examples from clinical electrophysiology and device therapy.

Indexed as

Atrial FibrillationElectrophysiologic Techniques, CardiacCost-Benefit AnalysisHealth Care CostsHumansQuality-Adjusted Life YearsTreatment OutcomeAntibacterial envelopeCardiac electrophysiologyCardiac implantable electronic devicesCost-effectiveness analysisCost utilityEarly rhythm controlEconomyQuality-adjusted life year

Identifiers

PMID38289720
PMCPMC10858642
OpenAlexW4391673160

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.